Research Analysts Set Expectations for TLX FY2027 Earnings

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) – Analysts at William Blair dropped their FY2027 earnings per share estimates for shares of Telix Pharmaceuticals Limited American Depositary Shares in a research note issued to investors on Wednesday, March 12th. William Blair analyst A. Hsieh now forecasts that the company will post earnings per share of $1.44 for the year, down from their prior estimate of $1.46. William Blair has a “Outperform” rating on the stock. The consensus estimate for Telix Pharmaceuticals Limited American Depositary Shares’ current full-year earnings is $0.24 per share.

Separately, UBS Group boosted their price target on Telix Pharmaceuticals Limited American Depositary Shares from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, January 27th.

Telix Pharmaceuticals Limited American Depositary Shares Price Performance

Shares of NASDAQ:TLX opened at $17.16 on Thursday. Telix Pharmaceuticals Limited American Depositary Shares has a 1 year low of $14.01 and a 1 year high of $30.36. The business’s 50-day moving average price is $17.38.

About Telix Pharmaceuticals Limited American Depositary Shares

Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.